Scout Bio Successfully Completes Pilot Clinical Study of SB-001, a Single-Injection AAV Gene Therapy for the Treatment of Feline CKD-Associated Anemia
PHILADELPHIA, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Scout Bio today announced the successful completion of a CKD-associated anemia study in client owned cats treated with SB-001, an AAV expressing feline erythropoietin (fEPO). The study demonstrated a prolonged therapeutic effect with statistically significant increases in red blood cells after a single injection. SB-001 is the first gene therapy to successfully treat feline patients with an acquired non-monogenic disease. These results pave the way for Scout Bio’s portfolio of AAV delivered therapeutic proteins for companion animal diseases.
Clinical Study Highlights:
“In this study we have successfully shown that SB-001 has the ability to increase PCV into the normal range, thereby reducing or eliminating the clinical effects of anemia associated with CKD,” said Mark Heffernan, Ph.D., CEO of Scout Bio. “These exciting results reinforce the potential for Scout Bio’s gene therapy platform to advance treatments for other acquired chronic diseases such as diabetes, chronic pain and atopic dermatitis.”
There are no FDA-approved treatments available for CKD-associated anemia in cats The single injection treatment of SB-001 presents an enormous advantage in convenience, improved compliance, and potentially allows owners more quality time with their pets. “A new option for cats with kidney disease and anemia is urgently needed. These cats come into the veterinary clinic with weakness, lethargy, breathing difficulties, and overall feeling very unwell. SB-001’s ability to increase the PCV can make a huge difference for many of these cats that would otherwise face euthanasia,” said Anne Traas, DVM, MS, DACT, Chief Development Officer for Scout Bio and head of the clinical team leading the study. “It was very rewarding to hear from owners participating in the study who expressed their deep gratitude for the additional time SB-001 was able to provide their beloved pets.”
James M. Wilson, MD, PhD, Director of the Gene Therapy Program at the University of Pennsylvania and a co-founder of Scout Bio, commented, “Scout Bio’s focus in companion animals with chronic diseases has resulted in this successful demonstration that AAV gene therapy can be an effective alternative to frequent injections with therapeutic proteins and result in the improvement of feline patient lives. These results provide validation that Scout Bio’s platform can be used to successfully deliver therapeutic proteins to treat chronic diseases in companion animals.”
Scout Bio intends to progress key manufacturing activities and safety studies that will be necessary to apply for Expanded Conditional Approval under FDA guidelines.
About Chronic Kidney Disease (CKD)-Associated Anemia
About Scout Bio
University of Pennsylvania Financial Disclosure
For further information, please contact:
Killer Video Surveillance Solutions Across the Entire Cannabis Supply Chain
Mistakes VARs Can't Afford to Make in the Cannabis Market
Setting the Stage for 6G